Literature DB >> 30845856

Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma.

Binod Dhakal1, Adam Pagenkopf2,3, Muhammad Umair Mushtaq2,3, Ashley M Cunningham4, Evan Flietner2,3, Zachary Morrow2,3, Athanasios Papadas2,3, Chelsea Hope2,3, Catherine Leith5, Peiman Hematti2,3, Parameswaran Hari1, Natalie S Callander2,3, Fotis Asimakopoulos2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30845856      PMCID： PMC7176050          DOI： 10.1080/10428194.2019.1585836

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  14 in total

1.  Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade.

Authors:  H Suen; R Brown; S Yang; C Weatherburn; P J Ho; N Woodland; N Nassif; P Barbaro; C Bryant; D Hart; J Gibson; D Joshua
Journal:  Leukemia       Date:  2016-04-22       Impact factor: 11.528

2.  Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.

Authors:  Jeffrey Lee Jensen; Alexander Rakhmilevich; Erika Heninger; Aimee Teo Broman; Chelsea Hope; Funita Phan; Shigeki Miyamoto; Ioanna Maroulakou; Natalie Callander; Peiman Hematti; Marta Chesi; P Leif Bergsagel; Paul Sondel; Fotis Asimakopoulos
Journal:  Cancer Immunol Res       Date:  2015-05-04       Impact factor: 11.151

Review 3.  The multiple, complex roles of versican and its proteolytic turnover by ADAMTS proteases during embryogenesis.

Authors:  Sumeda Nandadasa; Simon Foulcer; Suneel S Apte
Journal:  Matrix Biol       Date:  2014-01-18       Impact factor: 11.583

4.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

Authors:  Stefani Spranger; Daisy Dai; Brendan Horton; Thomas F Gajewski
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

5.  Toll-like Receptor 2 Activation Promotes Tumor Dendritic Cell Dysfunction by Regulating IL-6 and IL-10 Receptor Signaling.

Authors:  Michael Tang; Jun Diao; Hongtao Gu; Ismat Khatri; Jun Zhao; Mark S Cattral
Journal:  Cell Rep       Date:  2015-12-17       Impact factor: 9.423

6.  Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade.

Authors:  Simone A Minnie; Rachel D Kuns; Kate H Gartlan; Ping Zhang; Andrew N Wilkinson; Luke Samson; Camille Guillerey; Christian Engwerda; Kelli P A MacDonald; Mark J Smyth; Kate A Markey; Slavica Vuckovic; Geoffrey R Hill
Journal:  Blood       Date:  2018-08-28       Impact factor: 22.113

7.  TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma.

Authors:  Camille Guillerey; Heidi Harjunpää; Nadège Carrié; Sahar Kassem; Tricia Teo; Kim Miles; Sophie Krumeich; Marianne Weulersse; Marine Cuisinier; Kimberley Stannard; Yuan Yu; Simone A Minnie; Geoffrey R Hill; William C Dougall; Hervé Avet-Loiseau; Michele W L Teng; Kyohei Nakamura; Ludovic Martinet; Mark J Smyth
Journal:  Blood       Date:  2018-07-09       Impact factor: 22.113

8.  IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells.

Authors:  Julian Plaumann; Melanie Engelhardt; Mohamed H S Awwad; Hakim Echchannaoui; Eva Amman; Marc S Raab; Jens Hillengass; Niels Halama; Brigitte Neuber; Carsten Müller-Tidow; Hartmut Goldschmidt; Michael Hundemer
Journal:  Cancer Immunol Immunother       Date:  2018-08-20       Impact factor: 6.968

9.  Immunoregulatory roles of versican proteolysis in the myeloma microenvironment.

Authors:  Chelsea Hope; Simon Foulcer; Justin Jagodinsky; Sarah X Chen; Jeffrey L Jensen; Sanjay Patel; Catherine Leith; Ioanna Maroulakou; Natalie Callander; Shigeki Miyamoto; Peiman Hematti; Suneel S Apte; Fotis Asimakopoulos
Journal:  Blood       Date:  2016-06-03       Impact factor: 22.113

10.  Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.

Authors:  Binod Dhakal; Aniko Szabo; Saurabh Chhabra; Mehdi Hamadani; Anita D'Souza; Saad Z Usmani; Rita Sieracki; Bishal Gyawali; Jeffrey L Jackson; Fotis Asimakopoulos; Parameswaran N Hari
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777
View more
  6 in total

Review 1.  Versican and Versican-matrikines in Cancer Progression, Inflammation, and Immunity.

Authors:  Athanasios Papadas; Garrett Arauz; Alexander Cicala; Joshua Wiesner; Fotis Asimakopoulos
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

Review 2.  Matrix proteoglycans in tumor inflammation and immunity.

Authors:  Gauri Deb; Alexander Cicala; Athanasios Papadas; Fotis Asimakopoulos
Journal:  Am J Physiol Cell Physiol       Date:  2022-07-25       Impact factor: 5.282

3.  Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.

Authors:  Sarah A Holstein; Fotis Asimakopoulos; Abdel Kareem Azab; Giada Bianchi; Manisha Bhutani; Leslie A Crews; Tom Cupedo; Hannah Giles; Sarah Gooding; Jens Hillengass; Lukas John; Shari Kaiser; Lydia Lee; Kylee Maclachlan; Marcelo C Pasquini; Flavia Pichiorri; Nina Shah; Monica Shokeen; Brian R Shy; Eric L Smith; Raluca Verona; Saad Z Usmani; Philip L McCarthy
Journal:  Transplant Cell Ther       Date:  2022-05-21

Review 4.  ADAMTS proteases and the tumor immune microenvironment: Lessons from substrates and pathologies.

Authors:  Silvia Redondo-García; Carlos Peris-Torres; Rita Caracuel-Peramos; Juan Carlos Rodríguez-Manzaneque
Journal:  Matrix Biol Plus       Date:  2020-12-30

Review 5.  Versican-A Critical Extracellular Matrix Regulator of Immunity and Inflammation.

Authors:  Thomas N Wight; Inkyung Kang; Stephen P Evanko; Ingrid A Harten; Mary Y Chang; Oliver M T Pearce; Carys E Allen; Charles W Frevert
Journal:  Front Immunol       Date:  2020-03-24       Impact factor: 7.561

Review 6.  The Cancer-Immunity Cycle in Multiple Myeloma.

Authors:  Mika Casey; Kyohei Nakamura
Journal:  Immunotargets Ther       Date:  2021-07-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.